Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Acquisitions (2023 - 2024)

Cytek Biosciences' Acquisitions history spans 2 years, with the latest figure at $471000.0 for Q4 2024.

  • For Q4 2024, Acquisitions changed N/A year-over-year to $471000.0; the TTM value through Dec 2024 reached $471000.0, down 98.95%, while the annual FY2024 figure was $471000.0, 98.95% down from the prior year.
  • Acquisitions reached $471000.0 in Q4 2024 per CTKB's latest filing, up from $1000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $44.9 million in Q1 2023 to a low of $1000.0 in Q3 2023.